The National Blood Authority (NBA) released the Guidelines on the Prophylactic Use of Rh D Immunoglobulin (Anti-D) in Obstetrics in 2003, with the aim of providing clinical guidance on antenatal prophylaxis. These guidelines also addressed supply constraints at the time of publication by including a staged implementation process for a full antenatal prophylaxis program in Australia.
In December 2014 there was an update of the Rh(D) Immunoglobulin-VF Product Information by CSL Behring regarding patients with a Body Mass Index (BMI) ≥30. As BMI was not addressed in the 2003 Guidelines, an expert panel was convened by the Australian Red Cross Blood Service and the NBA to develop an Expert Panel Consensus Position Statement regarding the use of Rh(D) immunoglobulin in patients with a Body Mass Index ≥30.
In October 2016, the NBA and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) agreed to update clinical guidance relating to antenatal prophylaxis in women who are Rh D negative, in accordance with current evidence and consensus among clinical experts.
A multidisciplinary Expert Reference Group (ERG) with expertise from a range of clinical settings was established to identify the key issues that should be investigated for a new evidence-based Guideline for the prophylactic use of Rh D immunoglobulin in maternity care. The following key areas of concern were identified and investigated:
- Does the available evidence still support universal routine antenatal prophylaxis?
- Should universal routine antenatal prophylaxis be moved from a two-dose regimen to a one-dose regimen?
- Should the list of sensitising events in the first 12 weeks of pregnancy be amended to include additional events?
- To reduce unnecessary use of Rh D immunoglobulin, should non-invasive prenatal screening be used in the first trimester so that prophylaxis can be targeted?*
- Does increasing BMI impact on the efficacy of Rh D immunoglobulin?
The draft guideline has been finalised and is now available for comment. Please visit the public consultation page for more details.
*The draft clinical guideline is not a policy statement on funding and supply arrangements for the national provision of non-invasive prenatal testing (NIPT) for blood group genotyping to determine the Rh D status of the fetus.
For more information please email email@example.com